Related Experiment Video

Updated: May 6, 2026

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System
12:18

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System

Published on: November 6, 2013

23.8K

A recombinant viruslike particle influenza A (H7N9) vaccine

Louis F Fries1, Gale E Smith, Gregory M Glenn

  • 1Novavax, Gaithersburg, MD lfries@novavax.com.

The New England Journal of Medicine
|November 15, 2013
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

8.0K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.3K

Related Experiment Videos

Last Updated: May 6, 2026

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System
12:18

Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System

Published on: November 6, 2013

23.8K
Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses
08:10

Production of High-Titer Infectious Influenza Pseudotyped Particles with Envelope Glycoproteins from Highly Pathogenic H5N1 and Avian H7N9 Viruses

Published on: January 15, 2020

8.0K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.3K

Related Concept Videos

Influenza01:27

Influenza

101
Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
101
Leaky Scanning02:28

Leaky Scanning

4.5K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R...
4.5K
Viral Recombination00:57

Viral Recombination

22.3K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
22.3K

Articles linked to this work by shared authors, journal, and citation graph.

Preclinical Development of ARV-2001, an Intradermally Administered mRNA-Lipid Nanoparticle Immunotherapeutic for the Treatment of HPV-16-Positive Cervical High-Grade Squamous Intraepithelial Lesions.

Vaccines·2026

Safety and immunogenicity of a COVID-19-Influenza Combination nanoparticle vaccine (CIC) containing SARS-CoV-2 recombinant spike and quadrivalent influenza hemagglutinin with Matrix-M® adjuvant: A phase 1/2 clinical trial.

Human vaccines & immunotherapeutics·2026

Nanoengineered cotton wipes for antiviral protection and environmental compatibility.

Scientific reports·2025

Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19).

Vaccine·2025

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

The Lancet. Microbe·2025

Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.

The Journal of infectious diseases·2024

Pulmonary Nodules.

The New England journal of medicine·2026

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

The New England journal of medicine·2026

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

The New England journal of medicine·2026

Catheter-Directed Thrombolysis in Intermediate-High-Risk Pulmonary Embolism.

The New England journal of medicine·2026

Timing of PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation.

The New England journal of medicine·2026

Pulmonary Denervation for Heart Failure-Related Pulmonary Hypertension.

The New England journal of medicine·2026

Interleukin-39 aggravates sepsis by inducing self-sustaining neutrophil activation in the lungs via the CXCL1-CXCR2 pathway.

International journal of biological sciences·2026

Mechanisms and clinical research progress of IL-6-mediated crosstalk between the alveolar microenvironment and the immune system in patients with severe pneumonia undergoing mechanical ventilation.

Frontiers in immunology·2026

Roles of IL-34 in neurological diseases: neuroprotection, inflammatory regulation, and myeloid plasticity.

Frontiers in immunology·2026

Inflammatory remodeling of the ovarian microenvironment in premature ovarian insufficiency: mechanisms and therapeutic opportunities.

Frontiers in immunology·2026

Recent understanding of immunometabolic remodeling in pulmonary macrophages: homeostasis, chronic respiratory diseases, and therapeutic targeting.

Frontiers in pharmacology·2026

RAC2 orchestrates immune cell actin remodeling and migration.

Frontiers in immunology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us